Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Parkinson's Disease
Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468
Phase 1 N=19 PF-06669571 In Subjects With Idiopathic Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Maximum Percent Change From Baseline in Movement Disorder Society-Sponsor Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Day 7…
Phase 2 N=22 A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants
N/A N=9 Effect of Exercise in Parkinsonism
Parkinson's Disease · Drug-induced Parkinsonism
Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units
Phase 3 N=427 Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's Disease
Primary: Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)…
N/A N=2,448 First Presentation of Parkinson Disease Patients to Neurologist
Parkinson Disease
Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
N/A N=51 Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
Parkinson Disease · Idiopathic Parkinson Disease
Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05
Phase 2 N=40 Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression
Parkinson Disease
Primary: Change in 18F-DTBZ Uptake in a Cohort of Parkinson's Disease Patients From Baseline to Month 36 — 12.95 SUVR
N/A N=57 Aerobic Exercise in Parkinson's Disease
Parkinson's Disease
Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05
Phase 3 N=336 Efficacy of Isradipine in Early Parkinson Disease
Parkinson Disease
Primary: Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score — 2.99; 3.26 score on a scale
Phase 3 N=40 Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Parkinson Disease · Orthostatic Hypotension
Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg
Phase 2 N=31 Parkinson's Disease Isradipine Safety Study
Parkinson's Disease
Primary: Tolerability of Isradipine Based on the Number of Participants That Complete the Study — 25 Participants
Phase 4 N=535 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
Parkinson Disease
Primary: Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15 — 0.3; 0.7 Units on a scale — p=0.6503
N/A N=221 Evaluation of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images
Diagnoses Disease
Primary: Sensitivity of mPDia for the Diagnosis of Neurodegenerative Parkinsonism — 94.30 percentage
Phase 4 N=19 Vigor and the LDR in Parkinson Disease
Parkinson Disease
Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min
N/A N=30 The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Longitudinal Change of Brain Network Activity — 0.41; 0.61; 2.21; 3.61 Z-score in PDRP — p=0.84
Phase 4 N=296 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinson Disease · Depression
Primary: Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12 — -4; -5.9 Score on scale — p=0.0103
Phase 2 N=142 Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
Parkinson Disease
Primary: Change in the Ratio of the Specific Striatal [123I]B-CIT Uptake to the Nondisplaceable Striatal [123I]B-CIT Uptake Between the Two Images — -2.6; -4.7; -3.7; -6.9…
Phase 2 N=137 A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Parkinson Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) — 19; 21; 21; 21 Participants
Phase 2 N=28 A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Advanced Parkinson's Disease
Primary: Levodopa Cmax Following First Dose on Day 1 — 2857.56; 2173.30 ng/mL
Phase 2 N=253 Dyskinesia in Parkinson's Disease (Study P04501)
Parkinson Disease · Movement Disorders · Central Nervous System Diseases
Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753
Phase 2 N=210 Pioglitazone in Early Parkinson's Disease
Parkinson's Disease
Primary: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to 44 Weeks — 4.42; 5.13; 6.25 units on a scale
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
Early Phase 1 N=54 Cognitive Rehabilitation in Parkinson's Disease
Parkinson's Disease
Primary: Reaction Time and Variability for Movement Task — 1013.858333; 994.94875; 979.2450877; 910.9120833 milliseconds
Phase 3 N=30 Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
N/A N=60 Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms
Parkinson Disease
Primary: Assessment of the Effectiveness of Two Months of Use of the Remedee Endorphin Band Medical Device in Improving Motor Disorders in Patients With Parkinson's Disease — 6…
Phase 3 N=778 A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
Parkinson Disease
Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700
N/A N=67 Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
Parkinson's Disease
Primary: AChE PET Neuroimaging — 0.0238; 0.0226 1/min — p=0.0009
Phase 3 N=172 A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
Parkinsonian Syndrome · Parkinson Disease(PD) · Multiple System Atrophy (MSA)
Primary: Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT Images — 0.851; 0.865; 0.919 ratio